Testagen (20 mg Vial) Dosage Protocol

Plan based on an 8–16 week daily protocol with gradual titration.

• Peptide Vials (Testagen, 20 mg each):
  • 8 weeks (~14 mg used) ≈ 1 vial
  • 12 weeks (~25 mg used) ≈ 2 vials
  • 16 weeks (~36 mg used) ≈ 2 vials
• Insulin Syringes (30‑ or 50‑unit recommended for low‑volume accuracy):
  • Per week: 7 syringes (1/day)
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
  • 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
  • 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
• Alcohol Swabs: One for the vial stopper + one for the injection site each day.
  • Per week: 14 swabs (2/day)
  • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
  • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
  • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Testagen 20 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
• Typical daily range: 100–300 mcg once daily (gradual titration).
• Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Testagen is a synthetic tetrapeptide with the sequence Lys‑Glu‑Asp‑Gly (KEDG), an anterior pituitary‑derived bioregulator studied for its role in modulating endocrine function, particularly the pituitary–gonadal axis^[1][2]. Preclinical research indicates effects on thyroid hormone normalization and male reproductive hormone modulation^[3][4]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Concise summary of the once‑daily regimen.

• Goal: Support endocrine function research, particularly pituitary–gonadal axis modulation^[1][2].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: 100–300 mcg daily with gradual titration.
• Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested daily titration approach.

• Start: 100 mcg daily; increase by ~50 mcg every 2 weeks as tolerated.
• Target: 200–300 mcg daily by Weeks 5–12.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container^[7].
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[8].
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Due to very low injection volumes (≤5 units), a 30‑ or 50‑unit syringe is recommended for precision.

Testagen (Lys‑Glu‑Asp‑Gly) belongs to a class of short bioregulatory peptides derived from anterior pituitary extracts^[1]. Preclinical research in avian models demonstrates that this tetrapeptide can normalize thyroid hormone levels in hypophysectomized subjects and modulate endocrine signaling along the pituitary–gonadal axis^[3][4]. These peptides are hypothesized to act through gene‑regulatory mechanisms influencing hormone synthesis and secretion^[2]. No human clinical trials exist; current understanding is extrapolated from preclinical and in vitro studies.

Observations from preclinical literature (no human trials available).

• Preclinical studies suggest normalization of thyroid hormone parameters in hypophysectomized models^[3][4].
• Research indicates potential modulation of male reproductive hormones via pituitary pathways^[2].
• No published human safety or efficacy data; side‑effect profile in humans remains unknown.
• Occasional mild injection‑site reactions (redness/itch) may occur with subcutaneous administration.

Complementary strategies for best outcomes.

• Maintain a balanced, nutrient‑dense diet supporting endocrine health.
• Engage in regular physical activity to support hormonal balance.
• Prioritize quality sleep (7–9 hours) to optimize endogenous hormone rhythms.
• Manage stress through mindfulness or other techniques to reduce cortisol interference.

General subcutaneous guidance from clinical best‑practice resources^[9].

• Clean the vial stopper and skin with alcohol; allow to dry^[7].
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[7][8].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[7].
• Rotate sites systematically (abdomen avoiding 2″ around navel, thighs, upper arms) to avoid tissue damage^[8].
• Use a fine gauge needle (23–25 G, ½–⅝″) for comfort^[7].

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. No human clinical trials exist for Testagen; all information is derived from preclinical research.

• 1
  
  MDPI Molecules
  - The Inhibitory Effect and Adsorption Properties of Testagen Peptide on Copper Surfaces (structural characterization)

  View Source
• 2
  
  MDPI Molecules
  - Peptide Regulation of Gene Expression: A Systematic Review (bioregulatory peptide mechanisms)

  View Source
• 3
  
  PubMed
  - Effects of hypophyseal Lys‑Glu‑Asp‑Gly peptide on immunity, hemostasis, and thyroid function in hypophysectomized chickens

  View Source
• 4
  
  PubMed
  - Effects of Lys‑Glu‑Asp‑Gly peptide on hormonal activity and thyroid morphology in hypophysectomized mature and old birds

  View Source
• 7
  
  CDC
  - Vaccine Administration: Subcutaneous Injection Technique (angle, site, no aspiration)

  View Source
• 8
  
  MedlinePlus
  - Subcutaneous (SQ) Injections: Patient Instructions (site rotation and technique)

  View Source
• 9
  
  PMC
  - Subcutaneous Drug Delivery: Pharmacologic Considerations and Clinical Practice

  View Source
• 12
  
  Pure Lab Peptides
  - Testagen (20 mg) product page (quality and batch documentation)

  View Source

Additional Research and Background

These sources provide related context and are not presented as support for a specific statement above.

• 1
  
  PMC
  - Subcutaneous Injection Route: Pharmacokinetics and Clinical Applications Review

  View Source
• 2
  
  NCBI Bookshelf
  - Best Practices for Injection (asepsis, preparation, and administration)

  View Source

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.